SG11201604849YA - INDAZOLE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS - Google Patents
INDAZOLE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTSInfo
- Publication number
- SG11201604849YA SG11201604849YA SG11201604849YA SG11201604849YA SG11201604849YA SG 11201604849Y A SG11201604849Y A SG 11201604849YA SG 11201604849Y A SG11201604849Y A SG 11201604849YA SG 11201604849Y A SG11201604849Y A SG 11201604849YA SG 11201604849Y A SG11201604849Y A SG 11201604849YA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor agonists
- indazole compounds
- indazole
- compounds
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN5852CH2013 | 2013-12-16 | ||
| PCT/IN2014/000116 WO2015092804A1 (fr) | 2013-12-16 | 2014-02-24 | Composés d'indazole en tant qu'agonistes de récepteur de 5-ht4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201604849YA true SG11201604849YA (en) | 2016-07-28 |
Family
ID=50736125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604849YA SG11201604849YA (en) | 2013-12-16 | 2014-02-24 | INDAZOLE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9951045B2 (fr) |
| EP (1) | EP3099675B1 (fr) |
| JP (1) | JP6161823B2 (fr) |
| KR (1) | KR101824154B1 (fr) |
| CN (1) | CN105873920B (fr) |
| AP (1) | AP2016009253A0 (fr) |
| AU (1) | AU2014369085B2 (fr) |
| BR (1) | BR112016013974B1 (fr) |
| CA (1) | CA2932428C (fr) |
| DK (1) | DK3099675T3 (fr) |
| EA (1) | EA029951B1 (fr) |
| ES (1) | ES2668873T3 (fr) |
| IL (1) | IL245948B (fr) |
| MX (1) | MX368017B (fr) |
| NZ (1) | NZ720879A (fr) |
| SG (1) | SG11201604849YA (fr) |
| WO (1) | WO2015092804A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3180333T3 (pl) | 2014-08-16 | 2020-12-28 | Suven Life Sciences Limited | Proces przygotowania na dużą skalę szczawianu 1-izopropylo-3-{5- [1-(3-metoksypropylo) piperydyn-4-ylo]-[1,3,4]oksadiazol-2-ilo}-1h-indazolu |
| TR201909997T4 (tr) * | 2015-02-13 | 2019-07-22 | Suven Life Sciences Ltd | 5-HT4 reseptör agonistleri olarak amid bileşikleri. |
| EP4317141A1 (fr) | 2022-08-04 | 2024-02-07 | Curia Spain S.A.U. | Procédé et intermédiaires pour la préparation de viloxazine et d'autres dérivés de morpholine substitués en 2 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5150393A (en) | 1992-10-13 | 1994-05-09 | Smithkline Beecham Plc | Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists |
| AU680453B2 (en) | 1992-11-05 | 1997-07-31 | Smithkline Beecham Plc | Piperidine derivatives as 5-HT4 receptor antagonists |
| CA2461159A1 (fr) | 2001-10-22 | 2003-05-01 | Pfizer Inc. | Composes d'imidazopyridine en tant que modulateurs du recepteur 5-ht4 |
| BRPI0409592A (pt) | 2003-04-21 | 2006-05-02 | Pfizer | compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3 |
| ES2338882T3 (es) | 2003-11-24 | 2010-05-13 | Pfizer, Inc. | Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4. |
| EP1701951B1 (fr) * | 2003-12-23 | 2010-02-10 | Serodus AS | Modulateurs de recepteurs peripheriques 5-ht |
| CA2588037A1 (fr) * | 2004-12-22 | 2006-06-29 | Theravance, Inc. | Composes d'indazole-carboxamide |
| DK1856114T3 (en) | 2005-02-25 | 2014-11-17 | Raqualia Pharma Inc | Benzisoxazol-DERIVATIVES |
| US7906532B2 (en) | 2005-07-22 | 2011-03-15 | Pfizer Inc. | Indazole derivatives |
| RU2569733C2 (ru) * | 2010-02-12 | 2015-11-27 | Раквалиа Фарма Инк. | Агонисты 5-нт4-рецепторов для лечения деменции |
| CN102762554A (zh) | 2010-02-16 | 2012-10-31 | 辉瑞大药厂 | 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 |
| BR112014001083B8 (pt) * | 2011-09-19 | 2022-06-14 | Suven Life Sciences Ltd | Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto |
-
2014
- 2014-02-24 JP JP2016539987A patent/JP6161823B2/ja active Active
- 2014-02-24 WO PCT/IN2014/000116 patent/WO2015092804A1/fr active Application Filing
- 2014-02-24 MX MX2016007857A patent/MX368017B/es active IP Right Grant
- 2014-02-24 KR KR1020167015974A patent/KR101824154B1/ko active IP Right Grant
- 2014-02-24 US US15/104,521 patent/US9951045B2/en active Active
- 2014-02-24 CA CA2932428A patent/CA2932428C/fr active Active
- 2014-02-24 ES ES14725246.4T patent/ES2668873T3/es active Active
- 2014-02-24 DK DK14725246.4T patent/DK3099675T3/en active
- 2014-02-24 BR BR112016013974-7A patent/BR112016013974B1/pt active IP Right Grant
- 2014-02-24 EA EA201691252A patent/EA029951B1/ru unknown
- 2014-02-24 EP EP14725246.4A patent/EP3099675B1/fr active Active
- 2014-02-24 AP AP2016009253A patent/AP2016009253A0/en unknown
- 2014-02-24 NZ NZ720879A patent/NZ720879A/en not_active IP Right Cessation
- 2014-02-24 CN CN201480068132.6A patent/CN105873920B/zh active Active
- 2014-02-24 AU AU2014369085A patent/AU2014369085B2/en not_active Ceased
- 2014-02-24 SG SG11201604849YA patent/SG11201604849YA/en unknown
-
2016
- 2016-05-31 IL IL245948A patent/IL245948B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20160311797A1 (en) | 2016-10-27 |
| AU2014369085B2 (en) | 2017-02-23 |
| IL245948B (en) | 2019-08-29 |
| MX2016007857A (es) | 2016-09-07 |
| JP2016540796A (ja) | 2016-12-28 |
| NZ720879A (en) | 2017-05-26 |
| CN105873920A (zh) | 2016-08-17 |
| WO2015092804A1 (fr) | 2015-06-25 |
| CA2932428A1 (fr) | 2015-06-25 |
| BR112016013974B1 (pt) | 2022-11-22 |
| CA2932428C (fr) | 2017-10-24 |
| AP2016009253A0 (en) | 2016-06-30 |
| EP3099675B1 (fr) | 2018-02-14 |
| MX368017B (es) | 2019-09-13 |
| US9951045B2 (en) | 2018-04-24 |
| IL245948A0 (en) | 2016-08-02 |
| BR112016013974A2 (pt) | 2017-08-08 |
| JP6161823B2 (ja) | 2017-07-12 |
| EP3099675A1 (fr) | 2016-12-07 |
| ES2668873T3 (es) | 2018-05-22 |
| AU2014369085A1 (en) | 2016-06-30 |
| CN105873920B (zh) | 2018-06-08 |
| KR101824154B1 (ko) | 2018-03-14 |
| DK3099675T3 (en) | 2018-05-22 |
| EA201691252A1 (ru) | 2016-12-30 |
| BR112016013974A8 (pt) | 2018-01-30 |
| EA029951B1 (ru) | 2018-06-29 |
| KR20160075832A (ko) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL248347A0 (en) | Compounds and preparations as agonists of toll-like receptor 7 | |
| IL248311B (en) | Compounds and preparations as agonists of toll-like receptor 7 | |
| AP2016009445A0 (en) | Muscarinic receptor agonists | |
| EP2906542A4 (fr) | Composés spiropipéridinyliques substitués utiles comme agonistes de gpr120 | |
| SG11201706501VA (en) | AMIDE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS | |
| HK1257166A1 (zh) | 作為大麻素受體2激動劑的苯基衍生物 | |
| SG11201604849YA (en) | INDAZOLE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS | |
| HK1251831A1 (zh) | 作為選擇性5-ht(2c)受體激動劑的環丙基甲胺 | |
| HK1217483A1 (zh) | 作爲 受體激動劑的 -氨基-喹啉- -甲酰胺衍生物 | |
| IL243730A0 (en) | Vasopressin-2 receptor agonists | |
| GB201312010D0 (en) | Receptor Agonists | |
| GB2512843B (en) | Rod support for use by anglers | |
| GB201419433D0 (en) | Dopamine D3 receptor antagonist compounds |